Supplemental Digital Content is available in the text.

The prevalence of suboptimal prescribing of medications is well documented. Patients are often undertreated or not offered therapeutic treatments that are likely to confer benefit. As a result, drug-related hospital admissions are common and often preventable. Improvements to the health-care system are clearly needed in order to maximize the benefits that can be derived from medications. Many countries are changing their primary health-care systems to improve the quality of health-care delivery. One main transformation is the use of multidisciplinary care teams to provide care in a coordinated manner often from the same location or by using the common medical record of the patients. It has been demonstrated that pharmacists can improve prescribing, reduce health-care utilization and medication costs, and contribute to clinical improvements in many chronic medical conditions, such as cardiovascular disease, diabetes, and psychiatric illness. However, the effect of integrating a pharmacist providing general services into a primary care group has not been extensively studied. The Integrating Family Medicine and Pharmacy to Advance Primary Care Therapeutics (IMPACT) project was designed to provide a real-world demonstration of the feasibility of integrating the pharmacist into primary care office practice. This article provides a description of the IMPACT project participants; the IMPACT practice model and the concepts incorporated in its development; some initial results from the program evaluation; sustainability of the model; and some reflections on the implementation of the practice model.

acceptable reliability and good validity, which could be used to assess angina self-management, and also recommended to be used as an outcome along with quality of life to assess clinical efficacy. The risk-factor domain would be modified in the further study.

ObjectiveTo evaluate cost-utility of infliximab and adalimumab for the treatment of moderate-to-severe ulcerative colitis (UC) refractory to conventional therapies in Canada.MethodsA Markov model was constructed to evaluate incremental cost-utility ratios (ICUR) of 5 mg/kg and 10 mg/kg infliximab and adalimumab therapies compared to 'usual care' in treating a hypothetical cohort of patients (aged 40 years and weighing 80 kg) over a five-year time horizon from the perspective of a publicly-funded health care system. Clinical parameters were derived from the Active Ulcerative Colitis Trials 1 and 2. Costs were obtained through provincial drug benefit plans. ICUR was the main outcome measure and both deterministic and probabilistic sensitivity analyses were conducted.ResultsCompared to the strategy A ('usual care') in the base case analysis, the ICURs were CA$358,088/QALY for the strategy B ('5 mg/kg infliximab + adalimumab') and CA$575,540/QALY for the strategy C ('5 mg/kg and 10 mg/kg infliximab + adalimumab'). The results were sensitive to: the remission rates maintained in responders to 'usual care' and to 5 mg/kg infliximab, the rate of remission induced by adalimumab in non-responders to 5 mg/kg infliximab, early surgery rate, and utility values. When the willingness to pay (WTP) was less than CA$150,000/QALY, the probability of 'usual care' being the optimal strategy was 1.0. The probability of strategy B being optimal was 0.5 when the WTP approximated CA$400,000/QALY.ConclusionsThe ICURs of anti-TNF-α drugs were not satisfactory in treating patients with moderate-to-severe refractory UC. Future research could be aimed at the long-term clinical benefits of these drugs, especially adalimumab for patients intolerant or unresponsive to infliximab treatment.

Choice-based methods have been used widely in assessing healthcare programs. This study compared the binary discrete choice experiment (DCE) and the multiprofile case of best-worst scaling (BWS) in eliciting preferences for the EQ-5D-5L. Forty-eight EQ-5D-5L health states were selected using a Bayesian efficient design and grouped into 24 pairs for the DCE tasks and 8 sets for the BWS tasks (each set has three health states). A total of 100 participants completed 12 pairs and 8 sets in a random order. A probit regression model and ranked order logistic regression model were used to estimate the latent utilities from the DCE and BWS, respectively. Both tasks were well understood by the majority of participants. The DCE tasks were relatively easier and took a shorter time to complete. The intraclass correlation coefficient (ICC) of the DCE was higher than that of the BWS. The variances associated with the latent utilities estimated from the DCE were larger than those from the BWS. The DCE is more feasible and reliable than the BWS in valuing the EQ-5D-5L. Future studies could focus on comparing the consistency and accuracy of these techniques in predicting the health utilities of the EQ-5D-5L.